3-[(6-Methyl-4-oxothieno[2,3-d][1,3]oxazin-2-yl)amino]benzonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[(6-Methyl-4-oxothieno[2,3-d][1,3]oxazin-2-yl)amino]benzonitrile
• 化学式: C₁₄H₉N₃O₂S
• 分子量: 283.31
• InChiKey: SPZRTHBVUBQMAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
  申请人：Hodson Francis Harold

  公开号：US20050075336A1

  公开（公告）日：2005-04-07

  The use of a compound comprising formula (I), or a salt, ester, amide or prodrug thereof in the treatment of obesity and related disorders. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I): A is an optionally substituted thienyl moiety, Y is O, S, or NR 2 , R 1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups and R 2 is hydrogen or a group as defined for R 1 .

  使用具有式（I）的化合物，或其盐，酯，酰胺或前药治疗肥胖症及相关疾病。本发明还涉及公式（I）内的新化合物，制备它们的方法以及含有它们的制药组合物。在公式（I）中：A是可选择取代的噻吩基团，Y是O，S或NR2，R1是支链或非支链烷基（可被一个或多个氧原子中断），烯基，炔基，环烷基，环烷烯基，芳基，芳基烷基，还原芳基烷基，芳基烯基，杂环芳基，杂环芳基烷基，还原杂环芳基，还原杂环芳基烷基或任何上述基团的取代衍生物，R2是氢或与R1定义相同的基团。
• THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY
  申请人：HODSON Harold Francis

  公开号：US20090029978A1

  公开（公告）日：2009-01-29

  The use of a compound comprising formula (I), or a salt, ester, amide or prodrug thereof in the treatment of obesity and related disorders. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I): A is an optionally substituted thienyl moiety, Y is O, S, or NR 2 , R 1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups and R 2 is hydrogen or a group as defined for R 1 .

  使用公式（I）或其盐，酯，酰胺或前药治疗肥胖症及相关疾病。本发明还涉及公式（I）内的新化合物，制备它们的过程以及含有它们的制药组合物。在公式（I）中：A是可选择取代的噻吩基团，Y是O，S或NR2，R1是支链或直链烷基（可被一个或多个氧原子中断），烯基，炔基，环烷基，环烷烯基，芳基，芳基烷基，还原芳基烷基，芳基烯基，杂环芳基，杂环芳基烷基，还原杂环芳基，还原杂环芳基烷基或任何上述基团的取代衍生物，R2是氢或与R1定义相同的基团。
• US7407954B2
  申请人：——

  公开号：US7407954B2

  公开（公告）日：2008-08-05